Viswanath Devanarayan
Overview
Explore the profile of Viswanath Devanarayan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
2290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Devanarayan V, Ye Y, Zhu L, Tian L, Kramer L, Irizarry M, et al.
Alzheimers Dement
. 2025 Mar;
21(3):e70045.
PMID: 40042496
Background: Heterogeneity in Alzheimer's disease (AD) progression introduces variability in treatment effect assessments. Using predicted future progression as an AD prognostic covariate (APC) may reduce this variability. This study evaluates...
2.
Devanarayan V, Charil A, Horie K, Doherty T, Llano D, Andreozzi E, et al.
Alzheimers Dement
. 2024 Nov;
21(2):e14411.
PMID: 39575854
Background: This study examines whether phosphorylated plasma Tau217 ratio (pTau217R) can predict tau accumulation in different brain regions, as measured by positron emission tomography (PET) standardized uptake value ratio (SUVR),...
3.
Devanarayan V, Llano D, Hu Y, Hampel H, Kramer L, Dhadda S, et al.
Alzheimers Dement (Amst)
. 2024 Jul;
16(3):e12621.
PMID: 39045143
Abstract: Plasma pTau181, a marker of amyloid and tau burden, was evaluated as a prognostic predictor of clinical decline and Alzheimer's disease (AD) progression of amyloid-positive (Aβ+) patients with mild...
4.
Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease
Devanarayan V, Doherty T, Charil A, Sachdev P, Ye Y, Murali L, et al.
Alzheimers Dement
. 2024 Jun;
20(8):5617-5628.
PMID: 38940656
Background: This study investigated the potential of phosphorylated plasma Tau217 ratio (pTau217R) and plasma amyloid beta (Aβ) 42/Aβ40 in predicting brain amyloid levels measured by positron emission tomography (PET) Centiloid...
5.
Tourdot S, Baltrunkonis D, Denies S, Devanarayan V, Grudzinska-Goebel J, Kromminga A, et al.
MAbs
. 2024 Mar;
16(1):2324801.
PMID: 38441119
Biologics have revolutionized disease management in many therapeutic areas by addressing unmet medical needs and overcoming resistance to standard-of-care treatment in numerous patients. However, the development of unwanted immune responses...
6.
Devanarayan V, Ye Y, Charil A, Andreozzi E, Sachdev P, Llano D, et al.
Alzheimers Dement
. 2023 Dec;
20(3):1725-1738.
PMID: 38087949
Background: Models for forecasting individual clinical progression trajectories in early Alzheimer's disease (AD) are needed for optimizing clinical studies and patient monitoring. Methods: Prediction models were constructed using a clinical...
7.
Li G, Toschi N, Devanarayan V, Batrla R, Boccato T, Cho M, et al.
Alzheimers Res Ther
. 2023 Dec;
15(1):211.
PMID: 38057937
Background: Identifying individuals with mild cognitive impairment (MCI) who are likely to progress to Alzheimer's disease and related dementia disorders (ADRD) would facilitate the development of individualized prevention plans. We...
8.
Hong F, Tian L, Devanarayan V
Mathematics (Basel)
. 2023 Nov;
11(3).
PMID: 37990696
High-dimensional data applications often entail the use of various statistical and machine-learning algorithms to identify an optimal signature based on biomarkers and other patient characteristics that predicts the desired clinical...
9.
Llano D, Devanarayan P, Devanarayan V
Neurobiol Aging
. 2022 Nov;
121:15-27.
PMID: 36368195
The amyloid beta, tau, neurodegenerative markers framework has been proposed to serve as a system to classify and combine biomarkers for Alzheimer's Disease (AD). Although cerebrospinal (CSF) fluid AT (amyloid...
10.
Huang X, Tian L, Sun Y, Chatterjee S, Devanarayan V
Stat Med
. 2022 Sep;
41(26):5242-5257.
PMID: 36053782
Development of marker signatures to predict treatment benefits for a new therapeutic is an important scientific component in advancing the drug discovery and is an important first step toward the...